Cargando…
Revisiting the Medical Management of Parkinson's Disease: Levodopa versus Dopamine Agonist
The optimal treatment strategy for Parkinson's disease has been debated for decades. The introduction of levodopa (LD) treatment is frequently delayed because of theoretical concerns about its toxicity or the risk of drug-induced motor complications. These concerns have resulted in “LD phobia”...
Autores principales: | Zhang, Jinglin, Tan, Louis Chew-Seng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876591/ https://www.ncbi.nlm.nih.gov/pubmed/26644151 http://dx.doi.org/10.2174/1570159X14666151208114634 |
Ejemplares similares
-
Levodopa Versus Dopamine Agonist after Subthalamic Stimulation in Parkinson's Disease
por: Picillo, Marina, et al.
Publicado: (2020) -
Dopamine and Levodopa Prodrugs for the Treatment of Parkinson’s Disease
por: Haddad, Fatma, et al.
Publicado: (2017) -
Polymeric nanoparticles for dopamine and levodopa replacement in Parkinson's disease
por: Alabrahim, Obaydah Abd Alkader, et al.
Publicado: (2022) -
Efficacy and safety of non‐ergot dopamine‐receptor agonists as an adjunct to levodopa in advanced Parkinson's disease: A network meta‐analysis
por: Chen, Xiang‐Ting, et al.
Publicado: (2022) -
The treatment of Parkinson's disease with dopamine agonists
por: Konta, Brigitte, et al.
Publicado: (2008)